JACC. Arterial Stiffening Relates to Arterial Calcification But Not to Noncalcified Atheroma in Women

Marina Cecelja, BSC, Benyu Jiang, PHD, Lisa Bevan, RGN, Michelle L. Frost, PHD, Tim D. Spector, MD, Phil J. Chowienczyk

Our aim was to examine the relationship of arterial stiffness to measures of atherosclerosis, arterial calcification, and bone mineral density (BMD); the heritability of these measures; and the degree to which they are explained by common genetic influences. Journal of the American College of Cardiology. Vol. 57, No. 13, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.

JACC. 2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice

Pieter C. Smits, MD, PHD, Elvin Kedhi, MD, Kees-Jan Royaards, MD, Kaiyum Sheik Joesoef, MD, Jochem Wassing, MD, Tessa A. M. Rademaker-Havinga, MSC, Eugene McFadden, MD

The purpose of this study was to compare the safety and efficacy of the Xience V (Abbott Vascular, Santa Clara, California) everolimus-eluting stent (EES) with the Taxus Liberté (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting stent (PES) at 2-year follow-up. Journal of the American College of Cardiology. Vol. 58, No. 1, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.

JACC. Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry

Philip Urban, MD, Alexandre Abizaid, MD, Adrian Banning, MD, Antonio L. Bartorelli, MD, Ana Cebrian Baux, PHD, Vladimír Džavıík, MD, Stephen Ellis, MD, Runlin Gao, MD, David Holmes, MD, Myung Ho Jeong, MD, Victor Legrand, MD, Franz-Josef Neumann, MD, Maria Nyakern, PHD, Christian Spaulding, MD, Stephen Worthley, MD, for the e-SELECT Investigators

The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). Journal of the American College of Cardiology. Vol. 57, No. 13, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097

JACC. Impact of the Everolimus-Eluting Stent on Stent Thrombosis A Meta-Analysis of 13 Randomized Trials

Usman Baber, MD, MS, Roxana Mehran, MD, Samin K. Sharma, MD, Somjot Brar, MD, MPH, Jennifer Yu, MD, Jung-Won Suh, MD, PHD, Hyo-Soo Kim, MD, PHD, Seung-Jung Park, MD, PHD, Adnan Kastrati, MD, Antoinette de Waha, MD, Prakash Krishnan, MD, Pedro Moreno, MD, Joseph Sweeny, MD, Michael C. Kim, MD, Javed Suleman, MD, Robert Pyo, MD, Jose Wiley, MD, Jason Kovacic, MD, PHD, Annapoorna S. Kini, MD, George D. Dangas, MD, PHD

We evaluated the impact of the everolimus-eluting stent (EES) on the frequency of stent thrombosis (ST), target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death in randomized controlled trials comparing the EES to non–everolimus-eluting drug-eluting stents (EE-DES). Journal of the American College of Cardiology. Vol. 58, No. 6, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.

JACC. Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization A Meta-Analysis of Randomized Trials Performed in the Era of Stents and Thienopyridines

David E. Winchester, MD, Xuerong Wen, MPH, William D. Brearley, MD, Ki E. Park, MD, R. David Anderson, MD, Anthony A. Bavry, MD, MPH

The purpose of this study was to investigate the efficacy and safety of glycoprotein IIb/IIIa inhibitors (GPIs) during elective percutaneous coronary intervention (PCI). Journal of the American College of Cardiology. Vol. 57, No. 10, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.

CIRCULATION. Bare Metal Stent Thrombosis and In-Stent Neoatherosclerosis

Original Articles Bare Metal Stent Thrombosis and In-Stent Neoatherosclerosis Kyohei Yamaji, MD, Katsumi Inoue, MD, Takuya Nakahashi, MD, Masahiko Noguchi, MD, Takenori Domei, MD, Makoto Hyodo, MD, Yoshimitsu Soga, MD, Shinichi Shirai, MD, Kenji Ando, MD, Katsuhiro Kondo, MD, Koyu Sakai, MD, Masashi Iwabuchi, MD, Hiroyoshi Yokoi, MD, Hideyuki Nosaka, MD, Masakiyo Nobuyoshi, MD and Takeshi Kimura, MD

Very late stent thrombosis (VLST) was reported to occur even in patients with bare metal stent (BMS) implantation, although the annual incidence of VLST after BMS was much lower than that after drug-eluting stent implantation. Pathophysiologic mechanisms of VLST after BMS implantation remain largely unknown. Copyright © 2012 American Heart Association. All rights reserved. Print ISSN: 1941-7640. Online ISSN:1941-7632

ICI MEETING 2010. The use of Cutting Balloon for Resistant Congenital Pulmonic Valve Stenosis

S. Gavri, Z. Perles, AJJT. Rein

Our data suggest this procedure to be safe and potentially useful to achieve partial relief on the stenosiswhen it is not achieved by standard balloon dilation. A Larger patient series with a control arm is needed to determine if the use of cutting balloon for resistant pulmonary valve stenosis is effective in the long term. INNOVATION IN CARDIVASCULAR INTERVENTIONS MEETING.

THE NEW ENGLAND JOURNAL OF MEDICINE. Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents

Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S.

New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis. However, it is unclear whether there are differences in efficacy and safety between the two types of stents on the basis of prospectively adjudicated end points endorsed by the Food and Drug Administration. The New England Journal of Medicine. Copyright © 2010 Massachusetts Medical Society. All rights reserved.

EUROPEAN HEART JOURNAL. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial

Juan Luis Gutiérrez-Chico, Robert Jan van Geuns, Evelyn Regar, Willem J. van der Giessen, Henning Kelbæk, Kari Saunamäki, Javier Escaned, Nieves Gonzalo, Carlo di Mario, Francesco Borgia, Eveline Nüesch, Héctor M. García-García, Sigmund Silber, Stephan Windecker, and Patrick W. Serruys

Aims: To compare the tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent (ZES) vs. a fluoropolymer-coated everolimus-eluting stent (EES) at 13 months, using optical coherence tomography (OCT) in an all-comers population of patients, in order to clarify the mechanism of eventual differences in the biocompatibility and thrombogenicity of the devices. European Heart Journal (2011) 32, 2454–2463. Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011.

CIRCULATION. Delayed Coverage in Malapposed and Side-Branch Struts With Respect to Well-Apposed Struts in Drug-Eluting Stents. In Vivo Assessment With Optical Coherence Tomography

Juan Luis Gutiérrez-Chico, MD, PhD, FESC; Evelyn Regar, MD, PhD, FESC; Eveline Nüesch, PhD; Takayuki Okamura, MD, PhD; Joanna Wykrzykowska, MD, PhD; Carlo di Mario, MD, PhD, FESC; Stephan Windecker, MD, PhD, FESC; Gerrit-Anne van Es, MSc, PhD; Pierre Gobbens, MSc; Peter Jüni, MD; Patrick W. Serruys, MD, PhD, FESC

Pathology studies on fatal cases of very late stent thrombosis have described incomplete neointimal coverage as common substrate, in some cases appearing at side-branch struts. Intravascular ultrasound studies have described the association between incomplete stent apposition (ISA) and stent thrombosis, but the mechanism explaining this association remains unclear. Whether the neointimal coverage of nonapposed side-branch and ISA struts is delayed with respect to well-apposed struts is unknown. Copyright © 2011 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539.

AMERICAN HEART JOURNAL. Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents

Josep Gomez-Lara, MD, Jung Ho Heo, MD, Salvatore Brugaletta, MD, Scot Garg, MBChB, MRCP, Hector M. Garcia-Garcia, MD, PhD , Robert Jan van Geuns, MD, PhD , Sigmund Silber, MD, Stefan Windecker, MD, Patrick W. Serruys, MD, PhD

Vessel angulation and large changes in vessel geometry after stent implantation have been associated with an increased risk of target lesion failure (TLF) using bare-metal stents. Second-generation drug-eluting stents (DES)offer superior conformability and inhibition of neointima. The aim of the study is to investigate the relationship between pre and post-implant vessel geometry and the occurrence of TLF at 1 year after treatment with second-generation DES; and to compare the conformability of Resolute and Xience stents. American Heart Journal Volume 162. Copytight © 2011, Mosby, Inc. All rights reserved.

ARCHIVES OF CARDIOVASCULAR DISEASE. Transcatheter aortic valve replacement: A breakthrough medical therapy! The 20-year odyssey, and now, a 10-year anniversary

Martin B. Leon Columbia University Medical Center, Center for Interventional Vascular Therapy, New York Presbyterian Hospital, 161, Fort Washington Avenue, 6th Floor, New York, NY 10032, United States

The concluding statement from a first-in-man case report published in Circulation in 2002 was: ‘‘Nonsurgical implantation of a prosthetic heart valve can be successfully achieved with immediate and midterm hemodynamic and clinical improvement’’ [1]. The lead author of this short manuscript was Alain Cribier, and the procedure involved transcatheter placement of a bioprosthetic aortic valve in a desperately ill man with critical aortic stenosis (AS) and no therapy alternatives. At the time, it was impossible to predict the future of this new medical therapy, which at the same time appeared both reckless and revolutionary. In retrospect, 10 years later, this humble concluding statement laid the foundation for a medical breakthrough that has altered the landscape of cardiovascular medicine. The odyssey and the anniversary of transcatheter aortic valve replacement (TAVR) deserve our attention and careful reflection. Archives of Cardiovascular Disease (2012) 105, 129—131. Copyright © 2012 Published by Elsevier Masson SAS.

ARCHIVES OF CARDIOVASCULAR DISEASE. Prospective analysis of 30-day safety and performance of transfemoral transcatheter aortic valve implantation with Edwards SAPIEN XT versus SAPIEN prostheses

Hélène Eltchaninoff, Éric Durand, Bogdan Borz, Matthieu Godin, Christophe Tron, Pierre-Yves Litzler, Jean-Paul Bessou, Karim Bejar, Chiara Fraccaro, Carlos Sanchez-Girona, Jean-Nicolas Dacherc, Fabrice Bauer, Alain Cribier

A new generation of balloon-expandable valves (e.g. Edwards SAPIEN XT) enables the use of a decreased sheath size using the NovaFlexTM delivery system for transfemoral transcatheter aortic valve implantation (TAVI). However, there are few data analysing the efficacy and safety of this new prosthesis. Archives of Cardiovascular Disease (2012) 105, 132—140. Copyright © 2012 Elsevier Masson SAS. All rights reserved.

ARCHIVES OF CARDIOVASCULAR DISEASE. Transapical aortic valve implantation in Rouen: Four years’ experience with the Edwards transcatheter prosthesis

Pierre-Yves Litzler , Bogdan Borz, Hassiba Smail, Jean-Marc Baste, Catherine Nafeh-Bizet, Arnaud Gaya, Christophe Tron, Matthieu Godin, Jerome Caudron, Camille Hauville , Jean-Nicolas Dacher, Alain Cribier , Hélène Eltchaninoff, Jean-Paul Bessou

In April 2002, the first human percutaneous aortic valve implantation was performed in Rouen [1]. Different approaches quickly became feasible and, despite the historical use of the antegrade transseptal approach, the retrograde approach became popular during 2005, with the development of the RetroFlex catheter [2]. Due to the large diameter of the first models of the RetroFlex catheter (22/24 F) and the presence, in numerous patients, of small-calibre vessels or vascular disease, the idea of a transapical approach emerged. In 2005, after an animal feasibility study [3], the first patients were implanted via a small anterolateral mini thoracotomy [4,5]. In July 2007, the first transapical implantation in France was performed in our department. Since this time, 61 patients have been implanted using this approach. We report the 4-year outcomes of these patients. Archives of Cardiovascular Disease (2012) 105, 141—145. Copyright © 2012 Published by Elsevier Masson SAS.

ARCHIVES OF CARDIOVASCULAR DISEASE. Development of transcatheter aortic valve implantation (TAVI): A 20-year odyssey

Alain Cribier Service de cardiologie, hôpital Charles-Nicolle, université de Rouen, 1, rue de Germont, 76000 Rouen, France

The development of transcatheter aortic valve implantation (TAVI) by our group has been a 20-year odyssey. In 1993, postmortem studies validated the concept of intravalvular stenting in calcific aortic stenosis. The first prototypes of balloon-expandable valves were tested in an animal model in 2000. The first-in-man implantation was performed in Rouen in 2002, rapidly followed by two prospective series in compassionate cases in our centre. TAVI took flight in 2004 in the hands of Edwards Lifesciences, with major improvements in devices and approaches. At the same time, the self-expanding CoreValve was launched. Thousands of highsurgical- risk patients were enrolled in feasibility studies, leading to the Conformité Européenne (CE) mark being granted in 2007 for the two devices. Archives of Cardiovascular Disease (2012) 105, 146—152. Copyright © 2012 Elsevier Masson SAS. All rights reserved.